BRIEF-Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc.

INBX

0.00

May 11 (Reuters) - Inhibrx Biosciences Inc INBX.O:

  • INHIBRX REPORTS INTERIM PHASE 2 DATA FOR INBRX-106 IN FIRST-LINE HNSCC; INITIAL RESULTS DEMONSTRATE POTENTIAL COSTIMULATORY BENEFIT OVER PD-1 MONOTHERAPY

  • INHIBRX BIOSCIENCES INC - INBRX-106 PLUS PEMBROLIZUMAB ACHIEVES 44.0% CONFIRMED ORR VERSUS 21.4% WITH PEMBROLIZUMAB ALONE

  • INHIBRX BIOSCIENCES INC - THREE COMPLETE RADIOGRAPHIC RESPONSES OBSERVED WITH INBRX-106 PLUS PEMBROLIZUMAB

  • INHIBRX BIOSCIENCES INC - UP TO 15-FOLD INCREASE IN SYSTEMIC T-CELL EXPANSION WITH INBRX-106 PLUS PEMBROLIZUMAB

Source text: ID:nPn8skHlwa

Further company coverage: INBX.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.